Skip to content
value.today

Regentis Biomaterials Ltd.

Total raised
$7 M
1 round on record
Latest round
$7 M
Jun 2026
First round on record
Jun 2026
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Regentis Biomaterials Ltd.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2026$7 MNo. 1$2 to $10 million

Regentis Biomaterials Ltd.: Raise no. 1, Jun 2026

Investors in this round

22 investors had bought by the notice of Jun 25, 2026: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$455,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Israel

People named in the notice

  • Arie Gordashnikov · Executive Officer
  • Ehud Geller · Executive Officer, Director
  • Galit Reske · Executive Officer
  • Ori Gon · Executive Officer
  • Efraim Cohen-Arazi · Director
  • Jeff Dykan · Director
  • Keith Valentine · Director
  • Pini Ben-Elazar · Director
  • Susan Alpert · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • ThinkEquity LLC (CRD 000020996) · Ny, New YorkSold in AZ, CA, CT, FL, ID, IL, MA, NJ, NY, WA, WI, and outside the US

Remarks in the notice

  • On fees: “The Placement Agent also received a $180,000 accountable expense reimbursement, a non-accountable expense allowance of $65,000 and 92,857 unregistered warrants to purchase ordinary shares.”
  • On the amounts: “An offering of 1,844,543 ordinary shares, 12,600 pre-funded warrants and 1,857,143 ordinary warrants, at a purchase price of $3.50 per share and ordinary warrant and $3.4999 per pre-funded warrant and ordinary warrant.”
  • On the use of proceeds: “The Company intends to use the proceeds from the Offering to support its clinical trials and submissions to the FDA, advance its technology, support its operations and intellectual property and for working capital and general corporate purposes.”

Signed by Ori Gon, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 25, 2026. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Regentis Biomaterials Ltd. chose not to state its revenue in its newest notice of a funding round (Jun 2026).

    SEC Form D · Jun 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2026

That is all the official record says: Regentis Biomaterials Ltd. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Regentis Biomaterials Ltd. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 22 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Regentis Biomaterials Ltd.
NameRoleNamed in
Arie GordashnikovExecutive officerJun 2026
Ehud GellerExecutive officerJun 2026
Galit ReskeExecutive officerJun 2026
Ori GonExecutive officerJun 2026
Efraim Cohen-AraziDirectorJun 2026
Ehud GellerDirectorJun 2026
Jeff DykanDirectorJun 2026
Keith ValentineDirectorJun 2026
Pini Ben-ElazarDirectorJun 2026
Susan AlpertDirectorJun 2026